U.S. FDA, Industry Aim to Further Strengthen Pharma Supply Chain Quality
This article was originally published in PharmAsia News
While the pharmaceutical industry and U.S. FDA have made progress in better controlling the pharmaceutical supply chain since the heparin crisis a few years ago, they recognize that more needs to be done, said FDA and industry officials at a recent PDA/FDA Pharmaceutical Supply Chain Workshop in Bethesda, Md
You may also be interested in...
U.S. Pharmacopeia Ramps Up Drug Quality, Safety Cooperation Across Asia With Four New Agreements With China, ASEAN States
BEIJING - In moves that could ultimately help elevate safety and quality standards for drugs produced across Asia, including those exported to North America, the United States Pharmacopeial Convention has signed a series of agreements with China and the Association of Southeast Asian Nations on closer scientific exchanges and joint testing of pharmaceuticals
Drug manufacturers are forming a consortium called Rx-360 to take the lead in protecting the global pharmaceutical supply chain from threats like the heparin adulterant potentially linked to deaths of 146 U.S. patients last year
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).